Dr Pimlott is the principal radiochemist in the research and development radiopharmaceutical group, based at the Radionuclide Dispensary, Western Infirmary, Glasgow. Her research is focused on the development of novel molecular imaging agents. This includes:-
the development of novel radiolabelling methodologies
the synthesis and evaluation of novel tracer candidates using both in vitro and in vivo imaging techniques
the development of novel in vitro methodologies for the prediction of radiotracer in vivo characteristics.
Dr Pimlott is also experienced in the provision of radiopharmaceuticals for clinical research studies in compliance with Good Manufacturing Practice standards. Research is funded by the SINAPSE, Wellbeing of Women, Translational Medicine Research Collaboration (TMRC), Neurosciences Foundation, Chief Scientist Office (Scottish Executive), Medical Research Scotland and GE Healthcare.
Molecular Imaging Tracer Development Radiochemistry
Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans. Krishnadas R, Nicol A, Sassarini J, Puri N, Burden AD, Leman J, Combet E, Pimlott S, Hadley D, McInnes IB, Cavanagh J. Brain, Behavior, and Immunity Available online 6 August 2015
A novel 18F-labelled high affinity translocator protein agent for PET imaging. Blair A,Zmuda F, Malviya G, Chalmers AJ, Dewar D, Pimlott SL, Sutherland A. Chemical Science (2015) 6 4772-4777
Assessment of [¹²⁵I]WYE-230949 as a novel histamine H₃ receptor radiopharmaceutical. Lewis DY, Champion S, Wyper D, Dewar D, Pimlott S. PLoS ONE (2014) 9(12): e115876
Radioisotopes for Medical Imaging. Pimlott SL. International Journal of Modern Physics A (2014) 29 1441003
Targeting mTOR Dependency in Pancreatic Cancer. Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AYM, Scarlett CJ, Chang DK, Pajak MZ, Owen KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson K, Evans TRJ, Grimmond SM, Biankin AV, Sansom OJ, Morton JP. Gut (2014). 63:1481–1489.
Venlafaxine alters microvascular perfusion, [123I]beta-CIT binding and BDI scores in flushing postmenopausal women. Sassarini J, Krishnadas R, Cavanagh J, Nicol A,Pimlott SL, Ferrell W, Lumsden MA. Maturitas. (2014) 77 267-273.
Amyloid imaging with [11C]PIB in traumatic brain injury. Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJA, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK. JAMA Neurology (2014) 71:23-31
Structure-activity relationships of novel iodinated quinoline-2-carboxamides for targeting the translocator protein, Blair A, Stevenson L, Dewar D, Pimlott SL and Sutherland A. Med Chem Commun (2013) 4: 1461-1466
Nickel-Mediated Radioiodination of Aryl and Heteroaryl Bromides: Rapid Entry to Tracers for SPECT Imaging. Cant AA, Champion S, Bhalla R, Pimlott SL and Sutherland A. Angewandte Chemie International Edition (2013) 52: 7829-7832
Iodine-123 labelled reboxetine analogues for imaging of noradrenaline transporter in brain using single photon emission computed tomography. Tavares AAS, Jobson NK, Dewar D, Sutherland A, Pimlott SL, Batis J, Barret O, Seibyl J, Tamagnan G. Synapse (2012) 66:923-930.
Biodistribution and dosimetry of 123I-mZIENT: a novel ligand for imaging serotonin transporters. Nicol A, Krishnadas R, Champion S, Tamagnan G, Stehouwer JS, Goodman MM, Hadley DM, Pimlott S. Eur J Nucl Med Mol Imaging. (2012) 39: 786-791
Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides. Cant AA, Bhalla R, Pimlott SL, Sutherland A. Chem Comm. (2012) 48: 3993-3995
Radiotracer properties determined by high performance liquid chromatography: a potential tool for brain radiotracer discovery. Tavares AAS, Lewsey J, Dewar D, Pimlott SL. Nuc Med Biol. (2012) 39:127-135
Radiosynthesis of 123I-labelled benzimidazoles as novel SPECT tracers for the Histamine H3 receptor. Champion S, Gross J, Robichaud AJ, Pimlott S. Journal of Labelled Compounds and Radiopharmaceuticals. (2011) 54:674-677
Development of the Radiosynthesis of High Specific Activity 123I-NKJ64. Tavares AAS, Jobson NK, Dewar D, Sutherland A, Pimlott SL. Nuc Med Biol. (2011) 38:493-500
123I-NKJ64: A Novel SPECT Radiotracer for Imaging the Noradrenaline Transporter in Brain. Tavares AAS, Jobson NK, Dewar D, Sutherland A, Pimlott SL. Synapse. (2011) 65:658-667
Molecular tracers for the PET and SPECT imaging of disease. Pimlott SL and Sutherland A. Chem Soc Rev. (2011) 40:149-162.
Alterations in nicotinic alpha4beta2 receptor binding in vascular dementia using (123)I-5IA-85380 SPECT: Comparison with regional cerebral blood flow. Colloby SJ, Firbank MJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED, O’Brien JT. Neuorbiol Aging. (2011) 32: 293-301
Aberdeen Biomedical Imaging Centre – Prof F Gilbert and colleagues Scotland
Clinical Research Imaging Centre (CRIC) – Prof D Newby and colleagues Scotland
Prof M Bradley, University of Edinburgh, Scotland
Prof K Ebmeier, University of Oxford United Kingdom
Translational Medical Research Council Scotland
Prof A Spivey, University College London United Kingdom
Dr R Krisnadas, University of Glasgow Scotland
Dr A Sutherland, University of Glasgow Scotland
Prof M Lumsden, University of Glasgow Scotland
Dr E Newman, University of Glasgow Scotland
Dr G Tamagnan and colleagues, Molecular Neuroimaging Ltd and Yale University, USA Scotland
Prof O Samson, Beatson Institute for Cancer Research Scotland
Prof T Evan, Beatson Institute for Cancer Research Scotland
Dr D Dewar, University of Glasgow Scotland
Dr J Cavanagh, University of Glasgow Scotland
Dr M Goodman and colleagues, Emory University, Atlanta, GA, USA International
Dr Jos Eersals and colleagues, VU university, Amsterdam, The Netherlands International
Molecular Insight Pharmaceuticals, Cambridge, MA, USA International
GE Healthcare, Medical Diagnostics International